Andrew Cheng - Jan 3, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jan 3, 2022
Transactions value $
$32,595
Form type
4
Date filed
1/4/2022, 08:21 PM
Previous filing
Dec 10, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $32.6K +53K +20.7% $0.62* 309K Jan 3, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Employee Stock Option (Right to Buy) Options Exercise $0 -53K -20.49% $0.00 206K Jan 3, 2022 Common Stock 53K $0.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter.